RMTI · Rockwell Medical, Inc.
$7.31
+0.53 (+7.82%)
At close · Jul 27
Market Cap
$261.69M
Shares
39.47M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$69.26M
-31.8%
FY2025
Net Income
-$5.31M
-1007.1%
FY2025
Gross Margin
16.89%
-0.3pp
FY2025
Operating Margin
-6.77%
-7.4pp
FY2025
Diluted EPS
-$1.50
-400%
FY2025
Operating Cash Flow
-$659K
-115.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2029 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| at least $100M | $70M – $75M | $67.68M | $69.26MG | $101.49M | $83.61M | $72.81M | $61.93M | $62.2M | $61.3M | $63.39M | $57.3M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $367.08K | $535.64K | $790.23K | — | — | -$4.15M | -$1.82M | -$951 | -$1844 | -$9701 | -$25.18K | |
| — | — | $56.13M | $57.56M | $84.01M | $74.91M | $68.73M | $64.35M | $59.47M | $58.46M | $64.97M | $53.6M | $46.53M | $46.41M | $45.64M | $45.72M | $43.15M | $43.32M | $49.69M | $46.84M | |
| — | — | $11.55M | $11.7M | $17.48M | $8.7M | $4.08M | -$2.42M | $2.73M | $2.84M | -$1.58M | $3.7M | $6.75M | $8.94M | $8.55M | $6.66M | $6.69M | $5.64M | $9.86M | $7.89M | |
| — | — | — | 16.89% | 17.23% | 10.41% | 5.6% | -3.91% | 4.38% | 4.63% | -2.5% | 6.46% | — | — | — | — | — | — | — | — | |
| — | — | — | $0 | $19K | $1.11M | $3.12M | $6.84M | $7.09M | $6.89M | $5.64M | $6.32M | $5.84M | $4.96M | $7.78M | $39.38M | $48.27M | $17.81M | $3.42M | $6.45M | |
| — | — | $2.21M | $2.35M | $2.75M | $2.13M | $2.09M | $5.73M | $7.87M | $9.05M | $1M | — | — | — | — | — | — | — | — | — | |
| — | — | $14.15M | $14.03M | $14.11M | $12.14M | $15.64M | $15.35M | $16.18M | $21M | $22.08M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $23.08M | $23.3M | $21.12M | $19.08M | $18.32M | $14.34M | $12.68M | $9.52M | $9.31M | $6.91M | |
| — | — | — | — | — | $300K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $2.19M | $2.18M | $1.44M | $576K | $668K | $834K | $788K | $650.14K | $514.36K | $762.37K | $822.29K | $996.32K | $1.01M | $1.09M | $1.18M | $1.39M | $1.23M | |
| — | — | — | $1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$4.81M | -$4.69M | $608K | -$6.67M | -$16.78M | -$30.34M | -$28.42M | -$34.53M | -$32.44M | -$25.92M | -$20.21M | -$15.1M | -$17.56M | -$47.06M | -$54.26M | -$21.68M | -$2.87M | -$5.48M | |
| — | — | — | -6.77% | 0.6% | -7.98% | -23.05% | -48.98% | -45.69% | -56.32% | -51.18% | -45.24% | — | — | — | — | — | — | — | — | |
| — | — | — | -$2.5M | $2.79M | -$5.23M | -$16.2M | -$29.67M | -$27.59M | -$33.74M | -$31.79M | -$25.41M | -$19.45M | -$14.28M | -$16.56M | -$46.05M | -$53.17M | -$20.51M | -$1.48M | -$4.25M | |
| — | — | $1.13M | $1.12M | $1.25M | $2.3M | $1.94M | $2.36M | $1.88M | $25K | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $211K | $33K | $22K | $238K | $392K | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$593K | -$623K | -$1.09M | -$1.77M | -$1.9M | -$2.34M | -$2.47M | $397K | $313.3K | $1634 | — | — | — | — | — | — | — | — | |
| — | — | — | -$5.31M | -$480K | -$8.44M | — | — | — | — | — | -$25.92M | -$19.4M | -$14.42M | -$21.33M | -$48.78M | -$54.02M | -$21.44M | -$2.68M | -$5.5M | |
| — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.53K | $0 | $0 | $0 | $0 | $2005 | $0 | — | |
| — | — | -$5.4M | -$5.31M | -$480K | -$8.44M | -$18.68M | -$32.67M | -$30.89M | -$34.13M | -$32.13M | -$25.92M | -$19.8M | -$14.42M | -$21.33M | -$48.78M | -$54.02M | -$21.44M | -$2.68M | -$5.5M | |
| — | — | — | -7.67% | -0.47% | -10.09% | -25.65% | -52.76% | -49.66% | -55.67% | -50.68% | -45.24% | — | — | — | — | — | — | — | — | |
| — | — | -$5.56M | -$5.47M | -$782K | -$8.59M | -$18.68M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$5.33M | -$5.24M | -$425K | -$8.6M | -$18.57M | -$32.68M | -$30.89M | -$34.14M | -$32.03M | -$25.05M | -$19.79M | -$15.14M | -$21.56M | -$48.75M | -$53.74M | -$21.51M | -$2.9M | — | |
| USD/shares | — | — | — | -$1.50 | -$0.30 | -$3.70 | -$13.10 | -$38.30 | -$45.10 | — | — | -$56.10 | -$42.90 | -$31.90 | -$57.20 | — | — | — | — | — |
| USD/shares | — | — | — | -$1.50 | -$0.30 | -$3.70 | -$13.10 | -$38.30 | -$45.10 | — | — | -$56.10 | -$42.90 | -$31.90 | -$57.20 | — | — | — | — | — |
| shares | — | — | — | 3.6M | 3.11M | 2.33M | 1.43M | 852.62K | 687.47K | 553.8K | 480.22K | 464.25K | 460.69K | 455.16K | 376.41K | 298.93K | 185.42K | 161.59K | 155.56K | — |
| shares | — | — | — | 3.6M | 3.11M | 2.33M | 1.43M | 852.62K | 687.47K | 553.8K | 480.22K | 464.25K | 460.69K | 455.16K | 376.41K | 298.93K | 185.42K | 161.59K | 155.56K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.86×
Peer median 1.91×
EV/EBIT
—
Peer median 34.34×
P/E (TTM)
—
Peer median 14.91×
Peer medians compare against the 53 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $69,258,000 | $101,489,000 | $83,612,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $60,358,000 | $92,258,000 | $74,343,000 | $65,765,000 | $55,391,000 | $56,578,000 | $54,792,000 |
| Non Us | $8,900,000 | $9,231,000 | $9,269,000 | $7,045,000 | $6,540,000 | $5,619,000 | $6,511,000 |
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Concentrate Products | $101,443,000 | $81,274,000 | $71,651,000 | $60,855,000 | — | $60,758,000 |
| Drug Revenue | $46,000 | $2,338,000 | $1,159,000 | $1,076,000 | — | $545,000 |
| License | — | — | — | — | $2,200,000 | — |
| Product | — | — | — | — | $60,000,000 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$4,691,000 | $608,000 | -$6,670,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -6.8% | 0.6% | -8% |